NL
This biopharmaceutical company develops anti-cancer therapies using synthetic lethal interaction and bioinformatics-based software as a medical device. By enhancing the effectiveness of chemotherapy, the company aims to improve treatment outcomes for cancer patients and advance research in regenerative medicine.
Updated 2 months ago
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IA
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This biopharmaceutical company develops anti-cancer therapies using synthetic lethal interaction and bioinformatics-based software as a medical device. By enhancing the effectiveness of chemotherapy, the company aims to improve treatment outcomes for cancer patients and advance research in regenerative medicine.